Health
New STRENGTH Analysis Reignites Debate on Omega-3 CV Benefits – Medscape
The new analysis showing no benefits linked to higher achieved levels of EPA casts doubt over the use of high-dose omega-3 fatty acid products for preventing cardiovascular…
Questions over the cardiovascular benefits shown in the REDUCE-IT trial with icosapent ethyl, a high-dose eicosapentaenoic acid (EPA) product, have been reignited with a new analysis from the STRENGTH trial showing no benefit of a high-dose combined omega-3 fatty acid product in patients who achieved the highest EPA levels and no harm in those with the highest levels of docosahexaenoic acid (DHA).
STRENGTH investigator Steven Nissen, MD, said these new results add to concerns about the positive…
-
Noosa News12 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News12 hours agoMotorcyclist dies in crash with truck
-
Noosa News13 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General18 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging